Modulating TLR4 Signaling via hnRNP K Binding Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for sepsis-related inflammation, such as antibiotics and glucocorticoids, can lead to an uncontrolled immune reaction due to increased activation of TLR4 receptors, and there is a lack of specific control over cytokine production and release by monocytes and macrophages through interventions in TLR4-dependent signaling pathways.
Innovation Solution
Development of compounds that modulate the binding of heterogeneous nuclear ribonucleoprotein K (hnRNP K) to specific mRNAs, using a peptide (KH3) or RNA oligonucleotide (2R), to regulate the TLR4 signaling pathway, thereby controlling the synthesis and release of cytokines and dampening excessive immune reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If conventional therapies (antibiotics and glucocorticoids) are used to treat sepsis-related inflammation, then cytokine release is reduced, but uncontrolled immune reaction occurs due to increased activation of TLR4 receptors
Solution Approach 1:
The patent introduces small interfering RNAs (siRNAs) as intermediary molecules that specifically target and silence mRNA encoding TLR4 signaling pathway components (such as MyD88, IRAK1, TRAF6, TAK1, IKKβ, NFκB, and AP-1). This intermediary approach allows precise control of cytokine production at the post-transcriptional level, reducing harmful cytokine release while avoiding the uncontrolled immune reaction caused by conventional therapies that broadly suppress inflammation or activate TLR4 pathways
Solution Approach 2:
The patent changes the regulatory parameter from protein-level inhibition (conventional therapies) to mRNA-level silencing using siRNAs. By introducing siRNAs that complementary bind to specific mRNA sequences in the TLR4 signaling pathway, the system achieves precise parameter control over cytokine synthesis, reducing cytokine release while maintaining immune response control through sequence-specific targeting
2Object-generated harmful factors
If TLR4 signaling pathway is completely blocked to control cytokine production, then inflammatory response is suppressed, but ability to combat infection is reduced
Solution Approach 1:
The patent applies partial action by using siRNAs to selectively silence specific mRNA targets within the TLR4 signaling pathway rather than completely blocking the entire pathway. The siRNAs target specific components (MyD88, IRAK1, TRAF6, TAK1, IKKβ, NFκB, AP-1) to modulate cytokine production to appropriate levels, maintaining sufficient immune defense while preventing excessive cytokine release that causes tissue damage
Solution Approach 2:
The patent implements feedback control through siRNA-mediated silencing of key regulatory nodes in the TLR4 pathway. By targeting mRNA encoding signaling components, the system creates a feedback mechanism that modulates cytokine production in response to infection signals, preventing runaway cytokine release while maintaining the pathway's ability to respond appropriately to pathogenic threats
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compounds for use in modulating the toll-like receptor 4 (TLR4) signaling pathway, as well as to a pharmaceutical composition comprising said compounds.